Lung Cancer
Henlius HLX10-020-SCLC302
Official Title: Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Study Purpose: To evaluate the effectiveness of HLX10 in combination with chemotherapy and radiation.
Status:
Pending